Defining meaningful attributes for the treatment of IBD from patients' perspective

(1) CHU de Liège et Université de Liège,Liège,Belgium

(2) Axentiva Solutions,Santa Cruz de Tenerife,Spain

(3) Sheba Medical Center,Ramat Gan,Israel

(4) Complejo Universitario de Santiago de Compostela,Santiago de Compostela,Spain

(5) University College London Hospitals,London,United Kingdom

(6) University of British Columbia,Vancouver,Canada

(7) University Hospital Munster, Department of Medicine B, Gastroenterology and Hepatology,Munster,Germany

(8) London North West Healthcare,London,United Kingdom

(9) The University of Calgary,Calgary,Canada

(10) Association Crohn-RCUH,Montigny-le-Tilleul,Belgium

(11) Canada Crohn´s and Colitis,Toronto,Canada

(12) Confederation of Spanish Associations of Patients with Crohn's Disease and Ulcerative Colitis (ACCU),Madrid,Spain

(13) Patient Representative,Dresden,Germany

(14) Crohn’s and Colitis Foundation of Israel,Tel Aviv,Israel

(15) AbbVie Inc.,Madrid,Spain

(16) Crohn-Colitis Care Unit (UACC), Hospital Universitari Vall d’Hebrón,Barcelona,Spain

This item was part of the IBD I (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019